

Press Release

EMBARGOED: 11:00 SGT, THURSDAY 22 FEBRUARY 2024

Daiichi Sankyo Singapore is Launched to Expand the Reach of its Antibody-Drug Conjugates for People Living with Cancer

Singapore, 22 February 2024 – Daiichi Sankyo Singapore Pte. Ltd. (hereafter, Daiichi Sankyo Singapore), a subsidiary of Daiichi Sankyo Company, Limited (TSE: 4568), has been launched.

Daiichi Sankyo Singapore will be dedicated to bridging unmet needs in oncology, in hopes of extending and improving the lives of cancer patients, with cancer accounting for almost 30% of all deaths in Singapore. Daiichi Sankyo Singapore will focus on antibody-drug conjugates (ADCs), a class of drugs that offer targeted precision and potent drug delivery to certain tumour types, by delivering potent cancer-killing agents directly to cancer cells to eliminate them, whilst limiting damage to healthy surrounding cells.

“Daiichi Sankyo’s decision to set up in Singapore reflects our strength as a global biomedical sciences hub and will further enrich our ecosystem with capabilities in precision therapeutics. We look forward to seeing Daiichi Sankyo’s growth and efforts to bring forth novel drugs that would benefit patients around the world,” said Ms Goh Wan Yee, Senior Vice President and Head, Healthcare Division, Singapore Economic Development Board.

“Singapore has increasingly been becoming an important global hub for precision cancer treatment research and innovation. Therefore, with our proprietary DXd ADC technology, we are excited to contribute to improving outcomes for people living with cancer in Singapore,” said Koichi Morino, Managing Director of Daiichi Sankyo Singapore.

“We are committed to creating new employment and treatment opportunities in Singapore, and look forward to close partnership with the relevant professional and patient communities to bring forward new methods of drug delivery.”

As part of the Daiichi Sankyo Quality Assurance organisation, the newly set up RDPV QA (Research & Development, Pharmacovigilance, and Quality Assurance) function in Singapore signifies a strategic leap forward in reinforcing our commitment to patients, customers, and rigorous quality assurance in all that we do. This Asia Pacific regional hub will be a centre of excellence, driving the mission of 'Patient first, Quality Always' while ensuring the highest Quality standards in Research & Development, Pharmacovigilance, Medical Affairs and key processes and systems across the region.

“This is just the start of Daiichi Sankyo Singapore’s commitment to the local oncology ecosystem, beginning with our oncology expertise and the ambition to make a positive difference for Singaporeans in need of our current and future medicines,” said Koichi Morino.

Daiichi Sankyo’s portfolio currently consists of six DXd ADCs in clinical development across multiple types of cancer, with one of them now in commercialisation.



Passion for Innovation. Compassion for Patients.™

- ENDS -

About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.

Media Contacts:

Daphne Quek | E: daphne.quek@gcihealth.com | M: +65 9836 6993

Sheau Mey Lim | E: sheaumey.lim.uj@daiichisankyo.co.jp | M: +65 8031 0813